Archive: Company News
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
— HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptor
— Designed to target myeloid, NK and T cells and to be precisely directed to tumor sites
— Potent in vitro anti-tumor efficacy demonstrated
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
– Two renowned oncology experts to support the development of Thermosome’s clinical candidate THE001
Thermosome, a drug development company specializing in targeted tumor therapies, today announced the appointment of Dr. Frank Hermann, MD, as Chief Medical Officer (CMO) and the expansion of its Clinical Advisory Board with the addition of Prof. Alessandro Gronchi, MD.
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
— Presentation at the World Vaccine Congress West Coast2023
— EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodies
— Novel in-vitro data support preclinical proof-of-concept data
EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, has presented new in vitro data of its EBV-vaccine candidate EBV-001 at the World Vaccine Congress West Coast 2023 (Nov. 27-30, 2023) in Santa Clara, CA (USA). The presentation by EBViously’s designated COO Sebastian Goy was held on Thursday, November 30, 2023. Read more…